DEVELOPMENTAL RESEARCH PROGRAM

发展研究计划

• 批准号: 7664624
• 负责人: ROBERT E. TIGELAAR
• 金额: $ 26.19万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7664624
• 关键词: Artificial Intelligence; Basal cell carcinoma; Bioinformatics; Biostatistics Core; Chairperson; Clinical; Communities; Compatible; Complex; Comprehensive Cancer Center; Cost Sharing; Databases; Dermatology; Development; Diagnostic; Epidemiology; Epigenetic Process; Genetic; Genome; Genomics; Goals; Guidelines; Hospitals; Incidence; Internet; K-Series Research Career Programs; Molecular; Monitor; Other Resources; Pathology; Patients; Population; Preventive Intervention; Protein Microchips; Proteomics; Public Health; Reproduction spores; Research; Research Personnel; Resources; Serological; Serum; Skin Cancer; Source; Specimen; Support System; cancer Biomedical Informatics Grid; cost; density; early onset; immunoregulation; medical schools; melanoma; novel; novel strategies; prognostic; programs; response; statistics; tool; tumor

DESCRIPTION (provided by applicant): The Yale SPORE in Skin Cancer program is focused on two skin cancers, basal cell carcinoma (BCC) and melanoma. The goals are to conduct epidemiologic and genetic studies on early onset basal cell carcinoma (Project 1), establish novel high-throughput prognostic and diagnostic tools for melanomas (Projects 2 and 4), and introduce novel targeted therapies to treat melanoma (Projects 2 and 3). The new approaches include genome-wide monitoring of melanoma tumor responses to epigenetic modifiers (Project 2); the use of high-density protein microarrays (ProtoArrays) to interrogate serological responses in sera from melanoma patients (Project 4); and novel epigenetic modifier and immune modulation therapy for melanoma (Projects 2 and 3, respectively). The SPORE includes Administration, Specimen Resource and Bioinformatics/Biostatistics Cores to support the studies of SPORE investigators. Developmental Research and Career Development Award Programs are proposed. The Yale SPORE in Skin Cancer will be an integral part of the Yale Comprehensive Cancer Center (YCCC), Yale New Haven Hospital, and the Dermatology, Pathology and Epidemiology/Public Health Departments that collectively will provide the patient populations, specimens and other resources and support systems needed for the SPORE activities. There is a full commitment from the Dean of Yale School of Medicine and the Director of the YCCC/Chairman of Dermatology to support the SPORE with a plan for cost sharing. The major Translational Results expected are: a) Guidelines for preventive interventions aimed at reducing the incidence of early and total BCC that will diminish the management costs of the most common skin cancer; b) The introduction of new molecular tools for assessing responses to novel epigenetic modifiers; c) The introduction of new ways of assessing melanoma patients employing serological markers; d) The application of new approaches to personalize melanoma chemo- and immuno- therapy; e) The establishment of a composite databases for skin cancers that includes specimens tracking, clinical information, high throughput proteomics and genomics. The database program will be compatible with caBIG and will be available on the web for the benefit of the wider community of investigators and clinicians; f) The creation of new translational bioinformatics tools (predictive statistics and artificial intelligence) required to analyze global and highly complex information derived from different sources and different platforms.

描述（由申请人提供）：皮肤癌计划中的耶鲁孢子集中在两种皮肤癌，基底细胞癌（BCC）和黑色素瘤上。目标是对早期发作基础细胞癌进行流行病学和遗传研究（项目1），为黑色素瘤（项目2和4）建立新型的高通量预后和诊断工具（项目2和4），并引入了治疗黑色素瘤的新型靶向疗法（项目2和3）。新方法包括对黑色素瘤肿瘤对表观遗传修饰剂的反应的监测（项目2）；使用高密度蛋白微阵列（原始阵列）询问黑色素瘤患者血清学的血清学反应（项目4）；以及针对黑色素瘤的新型表观遗传修饰剂和免疫调节疗法（分别为项目2和3）。孢子包括给药，标本资源和生物信息学/生物统计学核心，以支持孢子研究者的研究。提出了发展研究和职业发展奖计划。耶鲁大学皮肤癌的孢子将是耶鲁大学综合癌症中心（YCCC），耶鲁纽黑文医院以及皮肤病学，病理学和流行病学/公共卫生部门不可或缺的一部分，这些部门将共同提供患者的人群，标本以及其他资源和其他资源和支持系统。耶鲁大学医学院院长和YCCC院长/皮肤病学董事主任致力于为孢子提供成本分担计划，以全力以赴。预期的主要翻译结果是：a）预防干预措施的指南，旨在减少早期和总BCC的发生率，从而降低最常见的皮肤癌的管理成本； b）引入了用于评估对新型表观遗传修饰剂反应的新分子工具； c）引入评估使用血清学标志物的黑色素瘤患者的新方法； d）应用新方法个性化黑色素瘤化学和免疫治疗的应用； e）建立用于皮肤癌的复合数据库，其中包括标本跟踪，临床信息，高通量蛋白质组学和基因组学。数据库计划将与Cabig兼容，并将在网络上提供，以便更广泛的调查员和临床医生社区的利益； f）创建新的翻译生物信息学工具（预测统计和人工智能），以分析源自不同来源和不同平台的全球和高度复杂信息。